Pre-clinical in vitro and in vivo studies have identified a number of candidate small molecule inhibitors that target the STAT3 signaling cascade, namely gp130, JAK and STAT3 itself, which inhibit growth and invasion of breast cancer models. Here, STAT3 is linked to breast carcinoma.